Product Description
Amisulpride, a substituted benzamide derivative, is a second-generation (atypical) antipsychotic. At low doses, it enhances dopaminergic neurotransmission by preferentially blocking presynaptic dopamine D2/D3 autoreceptors. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11735643/)
Mechanisms of Action: D2 Antagonist,D3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eagle
Company Location: WOODCLIFF LAKE NJ 07677
Company CEO: Scott Tarriff
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, France, Germany, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Other
Phase 2: Schizophrenia
Phase 1: Depressive Disorder, Major|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DP10027 | P3 |
Recruiting |
Other |
2025-06-20 |
82% |
| LB-102-003 | P2 |
Active, not recruiting |
Schizophrenia |
2024-10-15 |
|
| MSB-C002 | P1 |
Completed |
Depressive Disorder, Major |
2023-09-18 |
|
| QLG2069-AMS-301 | P3 |
Not yet recruiting |
Other |
2023-08-31 |
82% |